Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Michal Judith Besser, Ronnie Shapira‐Frommer, Avraham J. Treves et al. · Clinical Cancer Research · 2010
PURPOSE: Adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL) has shown promising results in metastatic melanoma patients. Although objective response rates of over 50% have been reported, disadvantages of this approach are the labor-intensive TIL production and a very high drop-out rate of enrolled patients, limiting its widespread applicability. Previous studies showed a clear correlation between short TIL culture periods and clinical response. Therefore, we used a new TIL production technique using unselected, minimally cultured, bulk TIL (Young-TIL). The use of Young-TIL is not restricted to human leukocyte antigen (HLA)-A2 patients. The purpose of this study is to explore the efficacy and toxicity of adoptively transferred Young-TIL following lympho-depleting chemotherapy in metastatic melanoma patients, refractory to interleukin-2 and chemotherapy. EXPERIMENTAL DESIGN: Young-TIL cultures for 90% of the patients were successfully generated, enabling the treatment of most enrolled patients. We report here the results of 20 evaluated patients. RESULTS: Fifty percent of the patients achieved an objective clinical response according to the Response Evaluation Criteria in Solid Tumors, including two ongoing complete remissions (20+, 4+ months) and eight partial responses (progression-free survival: 18+, 13+, 10+, 9, 6+, 4, 3+, and 3 months). All responders are currently alive. Four additional patients showed disease stabilization. Side effects were transient and manageable. CONCLUSION: We showed that lympho-depleting chemotherapy followed by transfer of short-term cultured TIL can mediate tumor regression in 50% of metastatic melanoma with manageable toxicity. The convincing clinical results combined with the simplification of the process may thus have a major effect on cell therapy of cancer.
Cited by 462 works. doi:10.1158/1078-0432.ccr-10-0041
Authors
- Michal Judith Besser
- Ronnie Shapira‐Frommer
- Avraham J. Treves
- Douglas B. Zippel
- Orit Itzhaki
- Liat Hershkovitz
- Daphna Levy
- Adva Kubi
- Einat Hovav
- Natalia Chermoshniuk
- Bruria Shalmon
- Izhar Hardan
- Raphael Catane
- Gal Markel
- Sara Apter
- Alon Ben‐Nun
- Iryna Kuchuk
- Avichai Shimoni
- Arnon Nagler
- Jacob Schachter
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Cancer immunotherapy: moving beyond current vaccines
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
- Management of Cutaneous Melanoma
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- Adoptive cell transfer: a clinical path to effective cancer immunotherapy
- High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
- Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients
- Adoptive cell therapy for the treatment of patients with metastatic melanoma